← Back to Home

Can Eye Drops Slow Pterygium Growth? CBT-001 Phase 3 Trial Reports Positive Results

A trial involving 659 patients showed that both doses improved hyperemia and slowed lesion progression, but adverse reactions on the corneal surface increased. Whether these findings translate into meaningful benefits for vision and the need for surgery remains unclear.

By SURL BioNews

Pterygium extends from the conjunctiva onto the cornea, causing more than just eye redness: continued growth may also affect vision. Eye drops that slow lesion progression could offer patients another treatment option. On November 5, Cloudbreak Pharma announced that its investigational drug CBT-001 outperformed a vehicle control containing no active drug in improving hyperemia and inhibiting lesion progression in a phase 3 study. However, the findings released so far are preliminary company results and are insufficient to determine whether the treatment can reduce the need for surgery.

According to the company’s announcement, the multinational, randomized, double-blind trial, called CS-301, enrolled 659 patients and compared twice-daily administration of 0.1% and 0.2% CBT-001 ophthalmic emulsion with vehicle. The ClinicalTrials.gov registration, NCT05456425, confirms that the study primarily assesses changes in conjunctival hyperemia at month 3 and changes in pterygium length at month 12. The overall dosing and safety follow-up plan covers 24 months, so these results do not mean that complete two-year data have been released.

The company said that both doses achieved statistically significant differences versus vehicle on both primary efficacy endpoints. Improvement in hyperemia appeared as early as week 2 and was maintained through month 12. For lesion length, the announcement described the benefit in the treatment groups relative to the vehicle group as approximately equivalent to 10% of baseline length. This is the difference in changes between the groups; it cannot be interpreted as meaning that every patient’s lesion shrank by 10%, nor can it be used to infer the extent of any improvement in vision.

CBT-001 uses a multikinase inhibition strategy targeting signaling associated with angiogenesis and fibrosis. Pterygium itself is a proliferation of vascularized fibrous tissue, which also explains why the study tracks both hyperemia and lesion length: the former reflects changes in the appearance of the ocular surface, while the latter assesses whether tissue continues to extend onto the cornea. However, more data are needed to establish the relationship between improvements in these two measures and patients’ everyday vision and quality of life.

Beyond efficacy, tolerability on the corneal surface is another key issue. Superficial punctate keratitis was reported by 20% of patients in the 0.1% group, compared with 8% in the vehicle group. The company said that most cases improved after the use of artificial tears. The types of adverse events in the 0.2% group were similar, but their incidence was higher; the announcement did not provide complete rates for that group. For patients who may need long-term use of the drops, this difference will affect dose selection and benefit-risk assessment.

The available data also leave points requiring clarification: the trial registry lists enrollment of 660 patients, while the company’s current results summary reports 659. The announcement has not explained this discrepancy. It also does not fully present the magnitude of efficacy changes in each group, confidence intervals, or treatment discontinuations. Statistical success therefore cannot yet fully answer how large the improvements are or which patients are most likely to benefit.

Cloudbreak said that further analyses are underway and that it plans to discuss the study results and next steps in development with the U.S. Food and Drug Administration (FDA) as soon as possible. This readout provides phase 3 evidence for drug treatment to address pterygium progression. Establishing its clinical role, however, still requires long-term safety data, complete efficacy analyses, and answers about outcomes patients experience more directly, such as whether surgery can be delayed.

References

  1. Cloudbreak Pharma via GlobeNewswire
  2. ClinicalTrials.gov